Vir Biotechnology stock surged 60% pre-market after strong Phase 1 cancer data and a partnership with Astellas. Raymond James upgraded the stock to Strong Buy with a $19 target, while Morgan Stanley raised its target to $24. Analysts praised the VIR-5500 results for exceeding expectations and strengthening Vir oncology platform.